IDT Australia (ASX:IDT) has disclosed FY26 revenue of $16.8 million across its three verticals, representing a 16.5% year-on-year increase from $14.4 million in FY25, as the company presented its Annual General Meeting materials outlining results and forward guidance for FY27.
Key Points
- FY26 revenue of $16.8M, up 16.5% from $14.4M in FY25, across API, Solid Oral and Sterile Manufacturing verticals
- EBITDA loss narrowed 85% from -$6.3M in FY25 to -$0.9M in FY26
- FY27 guidance targets revenue of $19.0M–$20.0M and EBITDA of $1.0M–$1.5M
- A five-year radiopharmaceutical contract signed with an existing client
- A approximately $7 million plant upgrade program described as fully funded and progressing to plan
FY26 Financial Results Across Three Verticals
According to the AGM presentation, IDT Australia recorded full-year revenue of $16.8 million in FY26, up from $14.4 million in FY25. The API vertical reported full-year revenue up 29% to $5.4 million, while Solid Oral Manufacturing revenue rose 52% to $5.5 million. Sterile Manufacturing revenue was down 11% to $5.9 million, with the filing attributing the movement to the timing of contracts. The company described Sterile Manufacturing as a key growth driver, noting mRNA demand and a Sanofi "Preferred Vendor" status. IDT Australia also received recognition at the Asia-Pacific RNA Excellence Awards 2026.
FY27 Guidance and Long-Term Revenue Target
The filing disclosed FY27 guidance of revenue between $19.0 million and $20.0 million, representing a forecast increase of 13% to 19% from FY26. EBITDA guidance for FY27 was set at $1.0 million to $1.5 million, compared to -$0.9 million in FY26, equating to a disclosed forecast improvement of 208% to 263%. The company stated a long-term target of $50 million in revenue by FY29. The filing noted the company's $50 million target represents less than 0.038% of its stated serviceable addressable market of more than US$130 billion across the US, EU and APAC regions.
Plant Upgrade Program and Five-Year Radiopharmaceutical Contract
IDT Australia disclosed an approximately $7 million plant upgrade program described as fully funded. The upgrade includes a new sterile manufacturing line using isolator technology for Grade A aseptic fill-finish, intended to enable commercial-scale fill-finish and serve ADCs, biologics, biosimilars, mRNA vaccines and specialty injectables. A solid oral dose upgrade covering tablet press, coating, solids handling and a complete bottle line was also disclosed as part of the program. Separately, the company announced a five-year radiopharmaceutical contract signed with an existing client, which the filing identified as a new contract in what it described as a fledgling segment.





_11_18_2026_12_41_48_650646.jpg)
Please wait processing your request...